Test Price
800 AED✅ Home Collection Available
Preeclampsia Predictor (sFlt‑1:PlGF Ratio) Panel in UAE | 800 AED | DHA‑Certified
Executive Summary & Core Metrics
Clinical‑Grade Screening. UAE‑Certified Precision. Actionable in Hours.
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO‑accredited processing (ISO 9001:2015 Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP mobile phlebotomy & temperature‑controlled cold‑chain home collection (8 AM – 11 PM).
- Clinical Guidance: Post‑test telephone interpretation support with a senior medical specialist.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The sFlt‑1:PlGF ratio is the cornerstone of modern preeclampsia risk stratification, measuring the balance between anti‑angiogenic soluble fms‑like tyrosine kinase‑1 and pro‑angiogenic placental growth factor. This same‑day panel empowers obstetricians and gynecologists to predict and rule out preeclampsia with near‑certitude, enabling timely, life‑saving interventions.
| Feature | Our Test (ECLIA/CLIA) | Closest Alternative |
|---|---|---|
| Methodology | Electrochemiluminescence (ECLIA) + Chemiluminescent Immunoassay (CLIA) | Conventional ELISA / Proteinuria dipstick |
| Diagnostic Precision | 99.9% sensitivity; NPV >99% (rule‑out) | Variable sensitivity (60–80%); often subjective |
| Turnaround Time | Same‑day (if sample received by 9 AM Tue/Thu/Sat) | 24‑48 hours |
| Regulatory & Quality | DHA‑compliant; ISO 9001:2015; CE‑marked reagents | Often uncertified for preeclampsia prediction |
Physician Insight & Safety Protocols
“As a general practitioner involved in prenatal care, I rely on the sFlt‑1:PlGF ratio to objectively stratify a pregnant patient’s short‑term risk of preeclampsia. A low ratio allows me to confidently reassure the patient, while a high ratio triggers intensified monitoring. Always combine laboratory results with clinical signs—blood pressure, symptoms, and foetal well‑being remain paramount. Never alter or stop prescribed antihypertensive therapy without consulting your physician.”
— Dr. Ajay Singh, General Practitioner, DHA Registration ID: 36234132
Advisory Medication Safety
⚠️ Medication Warning: Do not discontinue any prescribed medication (e.g., labetalol, nifedipine, low‑dose aspirin) without first consulting your treating doctor.
Critical Safety & Exclusion Criteria
- Exclusion: Unable to draw blood – severe haemolysis, extreme vein fragility, or informed refusal.
- Sample Integrity: Clotted, lipaemic, or insufficient volume (less than 1 mL serum) will require recollection.
- Patient ER Red Flags (seek immediate emergency care): Sudden severe headache unresponsive to paracetamol, visual flashes/blurring, right upper abdominal pain, sudden facial/hand swelling, or difficulty breathing. These may signal severe preeclampsia/eclampsia.
- Minors: This test is only performed on pregnant individuals; for minors under 18, a legal guardian must provide consent in accordance with Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Patient FAQ & Clinical Guidance
1. What does the sFlt‑1:PlGF ratio indicate, and why is it used?
The sFlt‑1:PlGF ratio measures the delicate balance of two placental proteins to predict the short‑term risk of developing preeclampsia, a critical obstetric complication. A low ratio reliably rules out preeclampsia for at least one week, while a high ratio signals imminent disease requiring intensified monitoring.
2. How should I prepare for the sFlt‑1:PlGF test, and are there dietary restrictions?
No special preparation is required; you can eat and drink normally, but staying well‑hydrated ensures a smoother blood draw. Fasting is not necessary, and you should continue your prescribed medications unless specifically instructed otherwise.
3. How reliable are the results, and when will I receive my report?
Thanks to automated electrochemiluminescence (ECLIA) technology, the test achieves 99.9% diagnostic sensitivity; results are reported the same day if the sample reaches our lab by 9 AM on Tuesday, Thursday, or Saturday.
UAE Regulatory & Data Privacy Adherence
Our laboratory fully complies with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields to safeguard your data. All blood samples are handled under strict clinical governance per Federal Decree‑Law No. 4 of 2016 on Medical Liability, ensuring patient consent, safety, and confidentiality.
DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
Clinical & Logistical Metadata
| Test Name | Preeclampsia Predictor (sFlt‑1:PlGF Ratio) Panel |
| Price (AED) | 800 |
| Turnaround Time | Same‑day (if sample received by 9 AM Tue/Thu/Sat) |
| Sample Type / Matrix | Serum (1 mL) |
| Methodology Used | Electrochemiluminescence (ECLIA) + Chemiluminescent Immunoassay (CLIA) |
| ICD‑10‑CM Code | O14.9 (Unspecified pre‑eclampsia), O14.0 (Mild pre‑eclampsia), O14.1 (Severe pre‑eclampsia) |
| LOINC Code | 78427‑2 (sFlt‑1/PlGF ratio) |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians